2026年开年以来,中国创新药(含创新制剂、生物药)在海外市场正迎来密集获批与上市申请受理,覆盖呼吸、肿瘤、罕见病等众多领域。如1月30日,康方生物宣布,美国食品药品监督管理局(FDA)已受理PD-1/VEGF双抗依沃西联合化疗治疗第三代EGFR-TKI治疗进展的EGFR突变的非鳞状非小细胞肺癌(NSCLC)的生物制品许可申请(BLA)。依沃西是国产双抗药物,2024年5月头个适应证在国内获批上市...
Source Link2026年开年以来,中国创新药(含创新制剂、生物药)在海外市场正迎来密集获批与上市申请受理,覆盖呼吸、肿瘤、罕见病等众多领域。如1月30日,康方生物宣布,美国食品药品监督管理局(FDA)已受理PD-1/VEGF双抗依沃西联合化疗治疗第三代EGFR-TKI治疗进展的EGFR突变的非鳞状非小细胞肺癌(NSCLC)的生物制品许可申请(BLA)。依沃西是国产双抗药物,2024年5月头个适应证在国内获批上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.